Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 3Colorectal Neoplasms 2Breast Neoplasms 2Solid Tumors 1Ovarian Neoplasms 1Multiple Myeloma 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Dexamethasone 129Lenalidomide 70Cyclophosphamide 70Bortezomib 69Calcium Dobesilate 50fludarabine 44pomalidomide 40daratumumab 37carfilzomib 33fludarabine phosphate 31Melphalan 25dexamethasone acetate 20dexamethasone 21-phosphate 20auricularum 18Filgrastim 18Whole-Body Irradiation 14Biopsy 13isatuximab 12Vorinostat 12Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Granulocyte Colony-Stimulating Factor 12Specimen Handling 11Sirolimus 11ixazomib 10belantamab mafodotin 10Panobinostat 10Mycophenolic Acid 10Cyclosporine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Multiple Myeloma × dalotuzumab × Clear all
NCT00701103 2018-08-08

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Merck Sharp & Dohme LLC

Phase 1 Completed
80 enrolled 23 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡